Dermatology Pipeline is Characterised by High Innovation, States GBI Research in Its In-demand Study Available at MarketPublishers.com

14 Mar 2017 • by Natalie Aster

LONDON – Nearly one-third of the population of the USA is affected by leastwise one active skin disease. For the last decades, the dermatology market has mostly remained saturated with entrenched and generic products. Nevertheless, with the success of biological drugs in the treatment of psoriasis alongside the progress in the understanding of the disease, pathways of a host of skin conditions have heightened the interest from pharmacos in the dermatology marketplace, which led to the building of an innovative pipeline.

Currently, more than 800 products are in active development in the dermatology therapeutic domain, with the greater part of products being small molecules. Biologics accounts for close to 40% of the pipeline, notwithstanding the fact that this type of molecules represents only a slight portion of the landscape of marketed products.

The dermatology pipeline is extremely innovative today. The number of robust products in late-stage development in tandem with the tremendous early-stage segment of this versatile and very active pipeline are some of the key factors fuelling this market’s growth over the long run.

Comprehensive study “Dermatology Therapeutics Drug Development Pipeline Review, 2016” created by GBI Research provides comprehensive insights into the pipeline development landscape for the skin conditions such as psoriasis, atopic dermatitis, and acne vulgaris, from discovery and up to the pre-registration phase. The study provides a granular assessment of the products by phase of development, MoA, RoA, molecular target, and molecule type. The research report contains a list of products in development, encompassing dormant and discontinued projects. Furthermore, the report gives an all-round overview of the leading players that are engaged in the development of products in the area discusses, and casts light on the latest updates and press announcements in the area.

More comprehensive reports prepared by this publisher, follow to the GBI Research page at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com